A phase 1, open-label, non-randomized, dose-finding, safety and tolerability study of orally administered Teysuno (S1) in combination with Epirubicin and Oxaliplatin in patients with advanced solid tumors - TPU-S1119

Trial Profile

A phase 1, open-label, non-randomized, dose-finding, safety and tolerability study of orally administered Teysuno (S1) in combination with Epirubicin and Oxaliplatin in patients with advanced solid tumors - TPU-S1119

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Epirubicin; Oxaliplatin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms TPU-S1119
  • Most Recent Events

    • 11 Aug 2015 Status changed from recruiting to completed.
    • 12 May 2014 New source identified and integrated (German Clinical Trials Register: DRKS00005941)
    • 12 May 2014 New source identified and integrated (German Clinical Trials Register: DRKS00005941)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top